Effect of prophylactic antiviral therapy on liver function injury and reactivation of HBV in elderly lung cancer patients with positive detection result of HBsAg
-
摘要: 目的 探讨预防性抗病毒治疗对乙肝表面抗原(HBsAg)阳性的老年肺癌患者肝功能损伤及乙肝病毒(HBV)再激活的影响。 方法 选取HBsAg阳性老年肺癌患者72例为HBsAg阳性组,其中给予预防性抗病毒治疗30例为干预组,未给予预防性抗病毒治疗42例为对照组; 另选择同期未合并HBV感染的老年肺癌患者72例为HBsAg阴性组。比较干预组、对照组及HBsAg阴性组肝功能损伤情况及HBV再激活情况。 结果 干预组肝功能损伤率为20.00%(6/30), 对照组肝功能损伤率为57.14%(24/42), HBsAg阴性组肝功能损伤率为22.22%(16/72)。干预组、HBsAg阴性组肝功能损伤率低于对照组,差异均有统计学意义(P<0.05)。干预组HBV再激活发生率为10.00%(3/30), 低于对照组的33.33%(14/42), 差异有统计学意义(P<0.05)。 结论 应用预防性抗病毒治疗HBsAg阳性老年肺癌患者安全、有效,能降低肝功能损伤的发生风险,预防HBV再激活。Abstract: Objective To explore the effect of prophylactic antiviral therapy on liver function injury and reactivation of hepatitis B virus(HBV)in elderly lung cancer patients with positive detection result of hepatitis B surface antigen(HBsAg). Methods Totally 72 elderly patients with HBsAg-positive lung cancer were selected as HBsAg-positive group, and 30 of them treated by prophylactic antiviral treatment were selected as intervention group, and 42 of them without prophylactic antiviral treatment were selected as control group. In addition, 72 elderly lung cancer patients without HBV infection in the same period were selected as HBsAg-negative group. The liver function injury and HBV reactivation in the intervention group, the control group and the HBsAg-negative group were compared. Results The rate of liver function injury was 20.00%(6/30)in the intervention group, 57.14%(24/42)in the control group and 22.22%(16/72)in the HBsAg-negative group. The rates of liver function injury in intervention group and HBsAg-negative group were significantly lower than that in control group(P<0.05). The incidence of HBV reactivation in the intervention group was 10.00%(3/30), which was significantly lower than 33.33%(14/42)in the control group(P<0.05). Conclusion It is safe and effective to treat the elderly patients with HBsAg-positive lung cancer by prophylactic antiviral therapy, which can reduce the risk of liver function injury and prevent HBV reactivation.
-
-
Lis C, Rubner S, Roatsch M, et al. Development of Erasin: a chromone-based STAT3 inhibitor which induces apoptosis in Erlotinib-resistant lung cancer cells[J]. Sci Rep, 2017, 7(1): 17390-17397.
王万敏, 韩一平. 预防性抗病毒治疗对乙肝表面抗原阳性肺癌患者肝功能损伤及乙型肝炎病毒再激活的影响研究[J]. 中国全科医学, 2019, 22(6): 683-686. 张佳佳, 王佳, 顾心雨, 等. HBsAg阳性肝细胞癌行介入术后复发的相关因素分析[J]. 中国实用医刊, 2017(21): 17-19. 丁建华, 汤巧云, 孙萍, 等. 晚期非小细胞肺癌患者化疗后肝损伤164例临床分析[J]. 肿瘤研究与临床, 2015, 27(1): 39-43. 罗皓, 周澄亚, 李力, 等. HBsAg(-)HBcAb(+)肿瘤患者化疗后HBV再激活3例报道并文献复习[J]. 肿瘤预防与治疗, 2017, 30(2): 107-111. 张崇建, 王璐, 王丽娜, 等. 乳腺癌患者化疗后肝功能损伤与乙型肝炎病毒感染的关系分析[J]. 中华医院感染学杂志, 2016, 26(4): 902-904. 贾万钧, 邓飞, 宋运娜. 慢性乙型肝炎病毒感染者与肝癌家族聚集性患者血清HBsAg和HBV-DNA检测的意义[J]. 中国肿瘤临床与康复, 2017, 24(2): 142-145. 庄衍, 唐勇, 俞夜花, 等. 长、短疗程口服抗病毒药预防急性髓系白血病患者乙型肝炎病毒再激活的观察研究[J]. 中国癌症杂志, 2017, 27(12): 964-969. 唐鲁兵, 范凤凤, 李占文, 等. 乳腺癌患者化疗后肝功能损害与乙肝病毒感染的临床分析[J]. 中国生化药物杂志, 2017, 37(5): 428-429 , 432.
Pattullo V. Prevention of Hepatitis B reactivation in the setting of immunosuppression[J]. Clin Mol Hepatol, 2016, 22(2): 219-237.
吴盛喜, 许鸿鹞, 黄河澄, 等. HBsAg阳性恶性肿瘤患者化疗后肝损伤及HBV再激活的临床分析[J]. 临床肝胆病杂志, 2016, 32(1): 110-113. Patel A, Yapali S, Lok A S. Admissions for hepatitis B reactivation in patients receiving immunosuppressive therapy remain unchanged from 1999 to 2014[J]. Hepatol Int, 2016, 10(1): 139-146.
杨永健, 宋辉. 拉米夫定预防非霍奇金淋巴瘤合并乙肝患者再激活的疗效观察[J]. 中外医学研究, 2016, 14(20): 34-35. 林玲, 常雅彬. 拉米夫定预防性应用对乳腺癌合并慢性乙型肝炎患者肝损伤及HBV再激活的疗效[J]. 医学临床研究, 2018, 35(6): 1146-1148.
计量
- 文章访问数: 390
- HTML全文浏览量: 120
- PDF下载量: 7
下载:
苏公网安备 32100302010246号